President Trump Announces Most-Favored-Nation Pricing Deal with Regeneron
Impact Score: 3.4
Timeline: Key milestones from May 12, 2025, through 2029 with phased implementation and Regeneron’s $27 billion domestic investment commitment.
Summary: President Trump unveiled the 17th MFN pricing agreement with Regeneron, aligning U.S. drug prices with the lowest in developed nations, yielding Medicaid savings and lowering medication costs such as Praluent. The deal includes Regeneron’s free gene therapy for rare deafness and mandates $27 billion in U.S. R&D investment by 2029. The initiative impacts multiple government agencies and healthcare programs, with potential risks to drug availability and research funding. Vanderbilt University and others are advised to adapt strategies and explore new partnerships amid changing drug pricing regulations.
Key Actions: Prepare for budget adjustments, advocate NIH funding, develop community education on pricing impacts, analyze public health effects, and incorporate healthcare law curriculum changes.
View Full Report
